1.13

0.88% -0.01

After Hours: 1.13

Bioxcel Therapeutics Inc (BTAI)

Overview News Price History Option Chain Financials Why BTAI Down? Discussions Forecast

Bioxcel Therapeutics Inc stock is traded at $1.13, with a volume of 348.91K. It is down -0.88% in the last 24 hours and down -1.74% over the past month. BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.

Previous Close:

$1.14

Open:

$1.15

24h Volume:

348.91K

Relative Volume:

0.23

Market Cap:

$34.89M

Revenue:

$642.00K

Net Income/Loss:

$-69.90M

P/E Ratio:

-0.158

EPS:

-7.152

Net Cash Flow:

$-57.62M

1W Performance:

-0.88%

1M Performance:

-1.74%

6M Performance:

-40.84%

1Y Performance:

-17.52%

1-Day Range:

$1.13

$1.175

1-Week Range:

$1.07

$1.19

52-Week Range:

$1.01

$8.08

Bioxcel Therapeutics Inc Stock (BTAI) Company Profile

Name

Bioxcel Therapeutics Inc

Sector

Healthcare (1108)

Industry

Drug Manufacturers - Specialty & Generic (86)

Phone

203-643-8060

Address

555 LONG WHARF DRIVE, NEW HAVEN, CT

Employee

Twitter

@bioxcel_tx

Next Earnings Date

2026-05-18

Latest SEC Filings

BTAI's Discussions on Twitter

Compare BTAI vs TAK, HLN, TEVA, ZTS, UTHR

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
BTAI Bioxcel Therapeutics Inc	1.13	35.20M	642.00K	-69.90M	-57.62M	-7.152
TAK Takeda Pharmaceutical Co Adr	16.25	52.07B	29.91B	1.30B	3.49B	0.4056
HLN Haleon Plc Adr	9.29	41.28B	14.54B	2.22B	2.58B	0.4871
TEVA Teva Pharmaceutical Industries Ltd Adr	34.07	39.78B	17.53B	1.58B	444.18M	1.3457
ZTS Zoetis Inc	81.32	33.57B	9.51B	2.64B	2.14B	6.0361
UTHR United Therapeutics Corp	568.43	24.02B	3.17B	1.29B	1.01B	27.09

Bioxcel Therapeutics Inc Stock (BTAI) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-17-26	Initiated	Rodman & Renshaw	Buy
Feb-21-24	Downgrade	UBS	Buy → Neutral
Aug-15-23	Downgrade	Mizuho	Buy → Neutral
Jul-17-23	Downgrade	Guggenheim	Buy → Neutral
Mar-10-23	Downgrade	Jefferies	Buy → Hold
Dec-01-22	Upgrade	Goldman	Sell → Neutral
Jul-07-22	Initiated	Mizuho	Buy
Apr-06-22	Reiterated	BofA Securities	Buy
Nov-15-21	Downgrade	Goldman	Neutral → Sell
Apr-09-21	Initiated	Berenberg	Buy
Feb-01-21	Initiated	UBS	Buy
Oct-30-20	Initiated	Goldman	Buy
Sep-02-20	Initiated	Jefferies	Buy
Aug-17-20	Reiterated	H.C. Wainwright	Buy
Jul-08-20	Reiterated	H.C. Wainwright	Buy
Jun-04-20	Initiated	Guggenheim	Buy
Apr-01-20	Initiated	BofA/Merrill	Buy
Feb-26-20	Reiterated	H.C. Wainwright	Buy
Jan-08-20	Reiterated	H.C. Wainwright	Buy
Nov-12-19	Initiated	SunTrust	Buy

View All

Bioxcel Therapeutics Inc Stock (BTAI) Latest News

May 23, 2026

BioXcel Therapeutics CEO Mehta sells $21,108 in company stock By Investing.com - Investing.com Nigeria

May 23, 2026

BioXcel Therapeutics chief legal officer sells $7,111 in stock By Investing.com - Investing.com Nigeria

May 23, 2026

BioXcel CFO Richard Steinhart sells $7,426 of stock By Investing.com - Investing.com India

May 23, 2026

BioXcel Therapeutics CSO Frank Yocca sells $7,426 in company stock By Investing.com - Investing.com Nigeria

May 23, 2026

May 22, 2026

BioXcel Therapeutics CEO Mehta sells $21,108 in company stock - Investing.com India

May 22, 2026

BioXcel CFO Richard Steinhart sells $7,426 of stock - Investing.com UK

May 22, 2026

BioXcel Therapeutics chief legal officer sells $7,111 in stock - Investing.com

May 22, 2026

BioXcel Therapeutics CSO Frank Yocca sells $7,426 in company stock - Investing.com

May 22, 2026

BioXcel Therapeutics (BTAI) CSO exercises 17,500 RSUs, sells 6,845 shares for tax payment - Stock Titan

May 22, 2026

BioXcel Therapeutics (BTAI) executive sells shares after RSU vesting for taxes - Stock Titan

May 22, 2026

BioXcel (BTAI) CFO exercises 17,500 RSUs and sells 6,845 shares for taxes - Stock Titan

May 22, 2026

BioXcel Therapeutics (BTAI) CEO sells shares to cover RSU tax obligations - Stock Titan

May 22, 2026

BioXcel Shareholder Notice - TMX Newsfile

May 22, 2026

BTAI Should I Buy - Intellectia AI

May 22, 2026

May 20, 2026

BioXcel Therapeutics (BTAI) Form 144: 19,419 RSUs vested, 30.9M shares outstanding - Stock Titan

May 20, 2026

BioXcel Therapeutics (NASDAQ: BTAI) notice to sell 6,560 vested restricted shares - Stock Titan

May 20, 2026

BioXcel Therapeutics (BTAI) Rule 144: 6,845 shares from vested RSUs - Stock Titan

May 20, 2026

[144] BioXcel Therapeutics, Inc. SEC Filing - Stock Titan

May 20, 2026

May 18, 2026

Is BioXcel Therapeutics (BTAI) Overvalued After Q1 2026? EPS Not - GuruFocus

May 18, 2026